DUBLIN--(BUSINESS WIRE)--The "Blood Cancer Drugs Global Market Report 2021: COVID-19 Impact and Recovery to 2030" report has been added to ResearchAndMarkets.com's offering.
Major players in the blood cancer drugs market are Amgen Inc., AstraZeneca PLC, Bayer AG, Celgene Corporation, and Eli Lilly.
The global blood cancer drugs market is expected to grow from $20.66 billion in 2020 to $21.6 billion in 2021 at a compound annual growth rate (CAGR) of 4.5%. The growth is mainly due to the companies rearranging their operations and recovering from the COVID-19 impact, which had earlier led to restrictive containment measures involving social distancing, remote working, and the closure of commercial activities that resulted in operational challenges. The market is expected to reach $28.7 billion in 2025 at a CAGR of 7.4%.
The blood cancer drugs market consists of sales of drugs to treat all types of blood cancers. The blood cancer drugs market excludes biologics and includes establishments that produce drugs used in chemotherapy, surgery and radio therapies for treating leukaemia, lymphoma, and myeloma.
The blood cancer drugs include Rituaxan/Mabthera (Rituximab), Gleevac/Glivec (Imatinib), Revlimid (Lenalidomide), Velcade (Bortezomib), Tasigna (Nilotinib), Pomalyst (Pomalidomide), Vidaza (Azacitidine), Kyprolis (Carfilzomib), Adcetris (Brentuximab Vedotin) and others.
In June 2019, FDA declined to approve Daiichi Sankyo's leukaemia drug for blood cancer treatment. Daiichi Sankyo, a global pharmaceutical company developing, importing and marketing pharmaceutical products received a rejection notice on its drug - quizartinib used for treating adults with a type of blood cancer.
The rejection of drug was due to the negative impact caused after the intake which resulted in FDA's statement saying faulty application for blood cancer treatment in an internal review. To avoid the incidences caused by such medicines in treating medical conditions such as blood cancer, FDA has declined to the approval.
The blood cancer drugs market is being driven by the growing death incidences and increasing prevalence of blood cancer cases across the globe. Different types of blood cancers such as lymphoma, leukaemia, myeloma and others have different risk factors where some can be controlled or prevented through drug therapies and others may lead to death. According to national cancer institute, the estimated deaths due to blood cancer are expected to be around 22,840 in 2019. The increasing deaths and increasing incidence of blood cancer cases globally drives the blood cancer drug market.
Drug approval involves series of research stages and regulatory approvals that are often expensive. Drug approval process include about four phases of clinical trials and various stages of screening process with the regulatory body such as FDA. The costs of failed clinical trials are also high as clinical trial phases involves huge investments.
Companies in the blood cancer drugs market are increasingly investing in technologies such as artificial intelligence (AI) to save time and reduce research and development costs. AI is the simulation of human intelligence processes by machines, especially computer systems, which has the potential to surpass human intelligence levels.
This technology helps to analyse large sets of chemical and biological data to identify potential drug candidates with higher success rates and at a quicker pace when compared to human analysis. The technology also helps in speeding up the patient recruitment process by matching blood cancer patients with the most relevant clinical trials, thus lowering clinical trial costs.
Major blood cancer drug manufacturers such as Roche, Pfizer and Johnson and Johnson have already invested in AI technologies to reduce time taken and costs incurred for drug development.
Key Topics Covered:
1. Executive Summary
2. Blood Cancer Drugs Market Characteristics
3. Blood Cancer Drugs Market Trends And Strategies
4. Impact Of COVID-19 on Blood Cancer Drugs
5. Blood Cancer Drugs Market Size And Growth
5.1. Global Blood Cancer Drugs Historic Market, 2015-2020, $ Billion
5.1.1. Drivers of the Market
5.1.2. Restraints on The Market
5.2. Global Blood Cancer Drugs Forecast Market, 2020-2025F, 2030F, $ Billion
5.2.1. Drivers of the Market
5.2.2. Restraints on the Market
6. Blood Cancer Drugs Market Segmentation
6.1. Global Blood Cancer Drugs Market, Segmentation By Blood Cancer Type , Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Leukemia
- Lymphoma
- Myeloma
6.2. Global Blood Cancer Drugs Market, Segmentation By Drugs, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Rituaxan/Mabthera (Rituximab)
- Gleevac/Glivec (Imatinib)
- Revlimid (Lenalidomide)
- Velcade (Bortezomib)
- Tasigna (Nilotinib)
- Pomalyst (Pomalidomide)
- Vidaza (Azacitidine)
- Kyprolis (Carfilzomib)
- Adcetris (Brentuximab Vedotin)
- Others
6.3. Global Blood Cancer Drugs Market, Segmentation By Treatment Approaches, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
- Key Findings
- Chemotherapeutic
- mAbs/Targeted Therapies
- Immunotherapeutic
7. Blood Cancer Drugs Market Regional And Country Analysis
7.1. Global Blood Cancer Drugs Market, Split By Region, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
7.2. Global Blood Cancer Drugs Market, Split By Country, Historic and Forecast, 2015-2020, 2020-2025F, 2030F, $ Billion
Companies Mentioned
- Amgen Inc.
- AstraZeneca PLC
- Bayer AG
- Celgene Corporation
- Eli Lilly
- Johnson & Johnson
- Novartis
- Pfizer Inc
- AbbVie Inc.
- Takeda Pharmaceutical Company Ltd
- F.Hoffmann-La Roche Ltd.
- Bristol-Myers Squibb Company
- Astellas Pharma Inc
- GlaxoSmithKline Pharmaceuticals Ltd
- Merck and Company
- Roche Holding AG
For more information about this report visit https://www.researchandmarkets.com/r/f57jwb
